AAP
INDV icon

Ardsley Advisory Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Ardsley Advisory Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119,500
Closed -$1.17M – 171
2024
Q3 		$1.17M Sell
119,500
-5,500
-4% -$64.4K 0.19% 91
2024
Q2 		$2.02M Buy
+125,000
New +$2.26M 0.3% 73

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Ardsley Advisory Partners's INDV Position: Q3 2025 in Review

Ardsley Advisory Partners sold out of Indivior Pharmaceuticals (INDV) in Q3 2025, closing a stake of 725,000 shares — an estimated $10.7M sold.

Ardsley Advisory Partners first reported a position in INDV in Q1 2024 and held it in 6 quarters. The position peaked at $14.9M in Q4 2024. 198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • Ardsley Advisory Partners reported no remaining Indivior Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ardsley Advisory Partners sold 725,000 Indivior Pharmaceuticals shares in Q3 2025, an estimated $10.7M.
  • Ardsley Advisory Partners first reported a position in Indivior Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Ardsley Advisory Partners's Indivior Pharmaceuticals position peaked at $14.9M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on Ardsley Advisory Partners's 13F filing for Q3 2025, filed 14 Nov 2025.